Xcout Intel
Centivax competitors & alternatives
The 12 closest competitors and alternatives to Centivax among biotechnology companies — ranked by similarity to what Centivax actually does, not by market-cap band.
Subscribe to see Centivax’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Centivax
Centivax is a privately held, clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on accelerating the transition to a post-pathogen world by developing broad-spectrum vaccines, COVID-19 therapeutics, and antivenom antibodies.
Centivax at a glance
Centivax is a biotechnology company headquartered in United States. It has raised at least $55M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $45M in July 2025. Xcout tracks 9 named people at Centivax, including Jacob Glanville (Chief Executive Officer).
Centivax leadership
- Jacob GlanvilleChief Executive Officer
- David TsaoChief Operating Officer
- Nicholas BaylessChief Technology Officer
- Gus ZeinerChief Innovation Officer
- Jerald SadoffChief Medical Officer
- Sawsan YoussefChief Science Officer
3 more named people on record for Centivax, with roles, board committees and tenure — see the full roster →
Centivax funding rounds
At least $55M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $45M | 6 named | |
| — | $10M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Centivax competitors
Ranked by semantic similarity — how close each company is to Centivax by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Antiva Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm focuses on biotechnology research and developing treatments for viral infections and precancerous conditions.
Similar biotechnology company
IgGenix is a clinical-stage, venture-backed biotechnology company founded in 2019 and headquartered in South San Francisco, California. The company leverages its proprietary antibody discovery platform with a primary mission to cure allergies and other immunological diseases.
Similar biotechnology company
Tizona Therapeutics, Inc. is a privately held immunology company founded in 2015 and headquartered in South San Francisco, California. The company focuses on harnessing the power of the immune system to develop treatments.
Similar biotechnology company
C3J Therapeutics, Inc. is a clinical-stage biotechnology company based in Los Angeles, California, focused on improving human health through the development of targeted antimicrobials.
Similar biotechnology company
MalarVx, Inc. is a clinical-stage biopharmaceutical vaccine company located in Seattle, Washington, founded to develop innovative vaccines addressing global infectious diseases.
Similar biotechnology company
Excision BioTherapeutics Inc. is a San Francisco-based clinical-stage biotechnology company focused on developing advanced gene editing therapeutics to treat infectious diseases.
Similar biotechnology company
Amphivena Therapeutics, Inc. is a privately held, clinical-stage biotechnology company based in South San Francisco, California. The company specializes in immuno-oncology, developing a platform of dual-function biologics and selective T cell engagers for the treatment of hematological conditions.
Similar biotechnology company
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Headquartered in California, the company advances a robust clinical pipeline and operates as a publicly traded enterprise.
Biotech
Bugworks Research Inc. is a clinical-stage biopharmaceutical company headquartered in Bangalore, India, developing novel therapeutics to combat antimicrobial resistance.
Similar biotechnology company
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Similar biotechnology company
Affinivax, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that pioneered a novel class of multiplex vaccine technologies.
Similar biotechnology company
Switch Therapeutics Inc. is a biotechnology company headquartered in South San Francisco, California. Founded in 2020, the company develops RNAi therapies based on its proprietary technology.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Centivax and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Centivaxand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →